This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hozumi, Y. Articles by Miyata, M. Search for Related Content PubMed PubMed Citation Articles by Hozumi, Y. Articles by Miyata, M.

Effect of Tamoxifen on Serum Lipid Metabolism

Departments of Surgery and Internal Medicine, Omiya Medical Center, Jichi Medical School, Omiya, Saitama 330, Japan

Address all correspondence and requests for reprints to: Dr. Hozumi Departments of Surgery and Internal Medicine, Omiya Medical Center, Jichi Medical School, 1–847 Amanuma-cho, Omiya, Saitama 330, Japan. E-mail: yahozumi{at}omiya.jichi.ac.jp

The effect of tamoxifen, an antiestrogenic agent, on lipid metabolism was studied in postmenopausal patients with breast cancer who received the drug for postoperative adjuvant treatment following mastectomy. To measure total cholesterol and triglyceride concentrations, fasting blood samples were collected before and 2 months after the initiation of tamoxifen therapy from 16 patients who satisfied the study criteria. All patients were normolipidemic before tamoxifen was administered. Control samples were obtained from hypertriglyceridemia patients who were free from breast cancer. Marked hypertriglyceridemia was observed in 3 of 16 patients after tamoxifen treatment. The activity of lipoprotein lipase and hepatic triglyceride lipase, the key enzymes of triglyceride metabolism, decreased significantly in all of 16 patients as a result of tamoxifen treatment (P = 0.008 and P = 0.007, respectively). However, the mean mass of lipoprotein lipase significantly increased (P = 0.011) after tamoxifen treatment. We therefore conclude that tamoxifen might increase inactive lipoprotein lipase. Because marked hyperlipidemia is a potent risk factor for life-threatening acute pancreatitis and arteriosclerosis, plasma lipid levels should be tested periodically during tamoxifen treatment, even if the patients are normolipidemic during the pretreatment stage.

This article has been cited by other articles:

				B. MELICHAR, H. KALABOVA, L. KRCMOVA, L. URBANEK, R. HYSPLER, D. SOLICHOVA, K. MELICHAROVA, M. PECKA, and Z. ZADAK Effect of Aromatase Inhibitors on Lipid Metabolism, Inflammatory Response and Antioxidant Balance in Patients with Breast Carcinoma Anticancer Res, August 1, 2009; 29(8): 3337 - 3346. [Abstract] [Full Text] [PDF]

				D. J. Lenihan and F. J. Esteva Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer Oncologist, December 1, 2008; 13(12): 1224 - 1234. [Abstract] [Full Text] [PDF]

				B. R.J. H. Bird and S. M. Swain Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems Clin. Cancer Res., January 1, 2008; 14(1): 14 - 24. [Abstract] [Full Text] [PDF]

				M. Kurt, M. O Babaoglu, U. Yasar, A. Shorbagi, and N. Guler Capecitabine-Induced Severe Hypertriglyceridemia: Report of Two Cases Ann. Pharmacother., February 1, 2006; 40(2): 328 - 331. [Abstract] [Full Text] [PDF]

				C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]